Atrial Fibrillation Clinical Trial
— AFFECTOfficial title:
Catheter Ablation for Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction
Verified date | October 2022 |
Source | University Hospital Heidelberg |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Atrial fibrillation (AF) displays high prevalence in heart failure with preserved ejection fraction (HF-PEF) and compromises prognosis of affected patients. This study aims to assess catheter ablation (CA) for AF in patients with HF-PEF compared to AF-patients without systolic or diastolic dysfunction. Primary endpoints are freedom from AF and quality of life at 1 year. Furthermore, the study is designed to elucidate mechanistic characteristics distinguishing arrhythmic substrate and predicting AF-recurrence in patients with HF-PEF. For this purpose, left atrial concentrations of biomarkers for inflammation, fibrosis and neurohumoral activation are determined and hemodynamic measurements are performed periprocedurally. Information on benefit from CA in these patients is necessary for clinical decision making and mechanistic investigations may point to tailored approaches in order to increase therapeutic efficiency.
Status | Completed |
Enrollment | 102 |
Est. completion date | February 2022 |
Est. primary completion date | September 2021 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Left ventricular ejection fraction =50% - Scheduled for catheter ablation of AF Exclusion Criteria: - Significant valvular heart disease - Coronary artery disease with >70% stenoses or necessary coronary Intervention at time of recruitment - Coronary intervention 60 days before recruitment - Coronary bypass surgery 90 days before recruitment - Cardiomyopathy or cardiac storage disease (e.g. amyloidosis) - Reduced left ventricular ejection fraction - Pericardiac disease - Significant pulmonary hypertension - Chronic obstructive pulmonary disease with home-oxygen-therapy, oral steroids, hospitalization due to exacerbations during the last 12 months before recruitment, or suspected severe pulmonary condition based on clinical evaluation - Other non-cardiac conditions associated with limited physical capacity (adipositas permagna, severe anemia) - Pregnancy - Other limitations for adequate performance of stress echocardiography (e.g. orthopedic reasons) |
Country | Name | City | State |
---|---|---|---|
Germany | University Hospital Heidelberg, Department of Cardiology | Heidelberg |
Lead Sponsor | Collaborator |
---|---|
University Hospital Heidelberg | Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Arrhythmia recurrence | Clinical arrhythmia and holter-recording | 12 months | |
Secondary | nTproBNP | [ng/L] | 12 months | |
Secondary | Troponin T | [pg/mL] | 12 months | |
Secondary | Systolic left ventricular function in echocardiography | LVEF [%] | 12 months | |
Secondary | Diastolic left ventricular function in echocardiography | E/e' | 12 months | |
Secondary | PA-pressure in echocardiography | [mmHg] | 12 months | |
Secondary | Quality of life questionnaire | SF-36 | 12 months | |
Secondary | Diastolic function in stressechocardiography | E/e' | 12 months | |
Secondary | 6-minute-walk-test | [m] | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |